Substance / Medication

Prazosin hydrochloride

Overview

Active Ingredient
prazosin
RxNorm CUI
8629

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

7 trials linked to this intervention

7
Total Trials
2
Recruiting
2
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Utilization of RESOLV with polymer to produce prazosin hydrochloride nanoparticles and optimization of the process parameters.
Ansari Eslam, Honarvar Bizhan, Sajadian Seyed Ali et al. · Sci Rep · 2024
PMID: 39112728OtherFull text (PMC)
Phosphate buffer interferes dissolution of prazosin hydrochloride in compendial dissolution testing.
Sudaki Hiroshi, Fujimoto Katsuyoshi, Wada Koichi et al. · Drug Metab Pharmacokinet · 2023
PMID: 37393739Other
Delivery of prazosin hydrochloride from osmotic pump system prepared by coating the core tablet with an indentation.
Liu Longxiao, Wang Jinchao, Zhu Suyan · Drug Deliv · 2007
PMID: 17497354Other
Structural characterization of prazosin hydrochloride and prazosin free base.
Chernyshev Vladimir V, Stephens Peter W, Yatsenko Alexandr V et al. · J Pharm Sci · 2004
PMID: 15514987Other
Preparation and transdermal diffusion evaluation of the prazosin hydrochloride-loaded electrospun poly(vinyl alcohol) fiber mats.
Shen Xiaobing, Xu Qian, Xu Shi et al. · J Nanosci Nanotechnol · 2014
PMID: 24758013Preclinical
Interpenetrating network hydrogel membranes of sodium alginate and poly(vinyl alcohol) for controlled release of prazosin hydrochloride through skin.
Kulkarni Raghavendra V, Sreedhar V, Mutalik Srinivas et al. · Int J Biol Macromol · 2010
PMID: 20678518Preclinical
Individual differences in the effects of chronic prazosin hydrochloride treatment on hippocampal mineralocorticoid and glucocorticoid receptors.
Kabbaj Mohamed, Morley-Fletcher Sara, Le Moal Michel et al. · Eur J Neurosci · 2007
PMID: 17552999Preclinical
Enhancer aided in vitro permeation of atenolol and prazosin hydrochloride through mice skin.
Reddy L H, Ghosh B · Indian J Exp Biol · 2001
PMID: 11349525Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Prazosin hydrochloride (substance)
SNOMED CT
387283005
UMLS CUI
C0700578
RxNorm CUI
8629

Clinical Data

This intervention maps to 9 entities in the Healos knowledge graph.

5
Conditions
1
Biomarkers
2
Specialists
0
Symptoms
7
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.